453 1031

Cited 25 times in

Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study

DC Field Value Language
dc.contributor.author김형중-
dc.contributor.author박혜성-
dc.contributor.author박혜정-
dc.contributor.author변민광-
dc.contributor.author이성수-
dc.contributor.author정희철-
dc.contributor.author조재용-
dc.contributor.author차윤진-
dc.date.accessioned2018-08-28T17:12:38Z-
dc.date.available2018-08-28T17:12:38Z-
dc.date.issued2018-
dc.identifier.issn2072-1439-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162371-
dc.description.abstractBackground: Lung cancer is being increasingly detected in the early stages, highlighting the importance of lung cancer screening. However, there is no consensus on the post-operative management of stage IB non-small cell lung cancer (NSCLC). Therefore, this study aimed to identify the predictive factors for prognosis of stage IB NSCLC and determine the efficacy of adjuvant chemotherapy on recurrence and survival. Methods: We enrolled 89 patients with stage IB NSCLC who underwent complete resection surgery at Gangnam Severance Hospital from Jan 2008 to Dec 2014. As per the National Comprehensive Cancer Network guidelines, patients were considered to be at high risk when they showed poorly differentiated tumors, lymphovascular invasion, tumor size >4 cm, and visceral pleural invasion (VPI). Results: Among the 89 patients, 27 underwent adjuvant chemotherapy. Young patients or patients with squamous cell lung cancer received adjuvant chemotherapy frequently. Adjuvant chemotherapy was not a significant factor for disease-free survival and overall survival. Adjuvant chemotherapy did not show a significant protective effect for survival, even for high-risk patients. However, VPI was a significant risk factor for disease-free survival [hazard ratio (HR): 7.051; 95% confidence interval (CI): 1.570-31.659; P=0.011] and overall survival (HR: 8.289; 95% CI: 1.036-66.307; P=0.046), even after adjustment for various factors. Conclusions: Adjuvant chemotherapy does not affect the prognosis of stage IB NSCLC, even in high-risk patients. Additionally, VPI is a strong prognostic factor of stage IB NSCLC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherPioneer Bioscience Pub. Co.-
dc.relation.isPartOfJOURNAL OF THORACIC DISEASE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleEfficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHye Jung Park-
dc.contributor.googleauthorHeae Surng Park-
dc.contributor.googleauthorYoon Jin Cha-
dc.contributor.googleauthorSungsoo Lee-
dc.contributor.googleauthorHei-Cheul Jeung-
dc.contributor.googleauthorJae Yong Cho-
dc.contributor.googleauthorHyung Jung Kim-
dc.contributor.googleauthorMin Kwang Byun-
dc.identifier.doi10.21037/jtd.2018.03.184-
dc.contributor.localIdA01158-
dc.contributor.localIdA01763-
dc.contributor.localIdA01769-
dc.contributor.localIdA01848-
dc.contributor.localIdA02866-
dc.contributor.localIdA03794-
dc.contributor.localIdA03899-
dc.contributor.localIdA04001-
dc.relation.journalcodeJ01907-
dc.identifier.eissn2077-6624-
dc.identifier.pmid29850132-
dc.subject.keywordLung cancer-
dc.subject.keywordadjuvant chemotherapy-
dc.subject.keywordearly stage-
dc.contributor.alternativeNameKim, Hyung Jung-
dc.contributor.alternativeNamePark, Heae Surng-
dc.contributor.alternativeNamePark, Hye Jung-
dc.contributor.alternativeNameByun, Min Kwang-
dc.contributor.alternativeNameLee, Sung Soo-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.alternativeNameCho, Jae Yong-
dc.contributor.alternativeNameCha, Yoon Jin-
dc.contributor.affiliatedAuthorKim, Hyung Jung-
dc.contributor.affiliatedAuthorPark, Heae Surng-
dc.contributor.affiliatedAuthorPark, Hye Jung-
dc.contributor.affiliatedAuthorByun, Min Kwang-
dc.contributor.affiliatedAuthorLee, Sung Soo-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.contributor.affiliatedAuthorCho, Jae Yong-
dc.contributor.affiliatedAuthorCha, Yoon Jin-
dc.citation.volume10-
dc.citation.number4-
dc.citation.startPage2279-
dc.citation.endPage2287-
dc.identifier.bibliographicCitationJOURNAL OF THORACIC DISEASE, Vol.10(4) : 2279-2287, 2018-
dc.identifier.rimsid59955-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.